Mesoblast(MESO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MESO Mesoblast

Closed 12-22 16:00:00 EST

19.42

-0.06

-0.31%

盘后19.42

+0.000.00%

19:02 EST

High19.52	Low19.15	Vol149.58K
Open19.43	D1 Closing19.48	Amplitude1.93%
Mkt Cap2.49B	Tradable Cap1.53B	Total Shares128.30M
T/O2.89M	T/O Rate0.19%	Tradable Shares78.65M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MESO","market":"US","secType":"STK","nameCN":"Mesoblast","latestPrice":19.42,"timestamp":1766437200000,"preClose":19.48,"halted":0,"volume":149581,"hourTrading":{"tag":"盘后","latestPrice":19.42,"preClose":19.42,"latestTime":"19:02 EST","volume":879,"amount":17071.37,"timestamp":1766448170925},"delay":0,"floatShares":78649063,"shares":128296718,"eps":-0.846,"marketStatus":"Closed","change":-0.06,"latestTime":"12-22 16:00:00 EST","open":19.43,"high":19.52,"low":19.145,"amount":2894417.1804460003,"amplitude":0.019251,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.846,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766480400000},"marketStatusCode":5,"adr":1,"adrRate":10,"listingDate":1447390800000,"exchange":"NASDAQ","adjPreClose":19.48,"preHourTrading":{"tag":"盘前","latestPrice":19.48,"preClose":19.48,"latestTime":"08:41 EST","volume":32,"amount":624.64,"timestamp":1766410895243},"postHourTrading":{"tag":"盘后","latestPrice":19.42,"preClose":19.42,"latestTime":"19:02 EST","volume":879,"amount":17071.37,"timestamp":1766448170925},"volumeRatio":0.460881,"impliedVol":0.5083,"impliedVolPercentile":0.348},"requestUrl":"/m/hq/s/MESO","defaultTab":"news","newsList":[{"id":"2592791957","title":"Has Mesoblast’s Surging Share Price Left Its Future Growth Prospects Underappreciated?","url":"https://stock-news.laohu8.com/highlight/detail?id=2592791957","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592791957?lang=en_us&edition=fundamental","pubTime":"2025-12-17 09:16","pubTimestamp":1765934210,"startTime":"0","endTime":"0","summary":"If you are wondering whether Mesoblast is a hidden bargain or a value trap at its current share price, you are not alone. This breakdown aims to unpack that question.\nThe stock has been choppy in the short term, down 1.8% over the last week. That comes after a 24.8% jump over the past month and a 42.8% gain over the last year, all against a still negative year to date return of 17.3% and a 215.8% rise over three years.\nRecent moves have been driven less by day to day noise and more by...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/has-mesoblasts-surging-share-price-left-its-future-growth-pr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/has-mesoblasts-surging-share-price-left-its-future-growth-pr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","BK7501","DCF","BK7508","BK4139","MESO","MSB.AU"],"gpt_icon":0},{"id":"2590526802","title":"Mesoblast Says Drug Candidate for Treatment of Severe Acute Graft Versus Host Disease Shows Superior Outcomes Than Ruxolitinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2590526802","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590526802?lang=en_us&edition=fundamental","pubTime":"2025-12-12 10:06","pubTimestamp":1765505219,"startTime":"0","endTime":"0","summary":"Mesoblast  said drug candidate Ryoncil  showed superior outcomes in complete and overall remission in a comparison study with ruxolitinib for treatment of steroid-refractory acute graft versus host disease, following an independent, peer-reviewed comparative study, according to a Friday filing with the Australian bourse.Shares of the company rose 2% in recent Friday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4181","BK4139","SPN","BK4218","BK7508","MSB.AU","BK7501","MESO","BK4585","BK4588","HST","BK7067"],"gpt_icon":0},{"id":"2590547736","title":"Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2590547736","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590547736?lang=en_us&edition=fundamental","pubTime":"2025-12-12 07:22","pubTimestamp":1765495320,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec.  11, 2025  (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that an independent pe","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3204384/0/en/Independent-Study-Presented-at-American-Society-of-Hematology-ASH-Annual-Meeting-Concludes-Remestemcel-L-Superior-to-Ruxolitinib-in-Clinical-Outcomes-as-Treatment-for-SR-aGvHD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4150","BK4139","BK4109","BK4117","MSB","BK4197","MESO","ASH","SR","MSC","BK4575","AFG","BK4006","SPN","BK4107","LU2463526074.USD"],"gpt_icon":0},{"id":"2588020600","title":"Mesoblast Participation at Piper Sandler Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2588020600","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588020600?lang=en_us&edition=fundamental","pubTime":"2025-12-04 07:10","pubTimestamp":1764803400,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec.  03, 2025  (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its participation at t","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/03/3199432/0/en/Mesoblast-Participation-at-Piper-Sandler-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","BK4139","MESO","MSB","BK4575","BK4150","MSC"],"gpt_icon":0},{"id":"2586259969","title":"Mesoblast’s AGM Results: All Resolutions Passed on November 25, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2586259969","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586259969?lang=en_us&edition=fundamental","pubTime":"2025-11-26 19:33","pubTimestamp":1764156827,"startTime":"0","endTime":"0","summary":"Mesoblast ( ($MESO) ) has provided an announcement. On November 25, 2025, Mesoblast Limited announced the results of its Annual General Meeting, wh...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mesoblasts-agm-results-all-resolutions-passed-on-november-25-2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mesoblasts-agm-results-all-resolutions-passed-on-november-25-2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGM","BK4195","MESO","BK4139","BK4229"],"gpt_icon":0},{"id":"2586474997","title":"BRIEF-Mesoblast Expects Gross Revenue Of More Than $30.0 Mln From Sales Of Ryoncil For Quarter Ending Dec 31","url":"https://stock-news.laohu8.com/highlight/detail?id=2586474997","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586474997?lang=en_us&edition=fundamental","pubTime":"2025-11-25 23:08","pubTimestamp":1764083338,"startTime":"0","endTime":"0","summary":"BRIEF-Mesoblast Expects Gross Revenue Of More Than $30.0 Mln From Sales Of Ryoncil For Quarter Ending Dec 31 Nov 25  - Mesoblast Ltd MSB.AX:MESOBLAST LTD - FOR QUARTER ENDING DECEMBER 31, 2025, EXPECTS GROSS REVENUE OF MORE THAN US$30.0 MILLION FROM SALES OF RYONCILSource text: [ID:n0001345099-25-000101]Further company coverage: MSB.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nFWN3X10UX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK7508","BK7067","MSB.AU","BK7501","MESO"],"gpt_icon":0},{"id":"2586474854","title":"Mesoblast Achieves FDA Approval for Ryoncil®","url":"https://stock-news.laohu8.com/highlight/detail?id=2586474854","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586474854?lang=en_us&edition=fundamental","pubTime":"2025-11-25 22:58","pubTimestamp":1764082704,"startTime":"0","endTime":"0","summary":"An update from Mesoblast ( ($MESO) ) is now available. On November 25, 2025, Mesoblast Limited announced at its Annual General Meeting that it has ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mesoblast-achieves-fda-approval-for-ryoncil?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mesoblast-achieves-fda-approval-for-ryoncil?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MESO","BK4139"],"gpt_icon":0},{"id":"2586471162","title":"Mesoblast Ltd - for Quarter Ending December 31, 2025, Expects Gross Revenue of More Than US$30.0 Million From Sales of Ryoncil","url":"https://stock-news.laohu8.com/highlight/detail?id=2586471162","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586471162?lang=en_us&edition=fundamental","pubTime":"2025-11-25 22:44","pubTimestamp":1764081869,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nFWN3X10UX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7501","BK7508","BK4139","MESO","MSB.AU"],"gpt_icon":0},{"id":"2586676476","title":"Mesoblast Raised to Buy From Hold by Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2586676476","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586676476?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:48","pubTimestamp":1764078480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MESO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 25, 2025 08:48 ET (13:48 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MESO"],"gpt_icon":0},{"id":"2586421222","title":"Mesoblast upgraded to Buy from Hold at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2586421222","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586421222?lang=en_us&edition=fundamental","pubTime":"2025-11-25 18:35","pubTimestamp":1764066918,"startTime":"0","endTime":"0","summary":"Jefferies upgraded Mesoblast (MESO) to Buy from Hold with a price target of A$3.30, up from A$3. Published first on TheFly – the ultimate source fo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mesoblast-upgraded-to-buy-from-hold-at-jefferies-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mesoblast-upgraded-to-buy-from-hold-at-jefferies-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MESO"],"gpt_icon":0},{"id":"2586416251","title":"Mesoblast Reports 37% Quarter-on-Quarter Revenue Growth From Ryoncil; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586416251","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586416251?lang=en_us&edition=fundamental","pubTime":"2025-11-25 07:53","pubTimestamp":1764028419,"startTime":"0","endTime":"0","summary":"Mesoblast  reported that gross revenue from Ryoncil sales is expected to exceed $30 million for the December quarter, marking over 37% increase from $21.9 million in the September quarter, according to a Tuesday Australian bourse filing.The company's shares rose around 3% in recent Tuesday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MESO"],"gpt_icon":0},{"id":"2586416150","title":"Press Release: Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil(R) Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2586416150","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586416150?lang=en_us&edition=fundamental","pubTime":"2025-11-25 07:39","pubTimestamp":1764027540,"startTime":"0","endTime":"0","summary":"NEW YORK, Nov. 24, 2025  -- Mesoblast Limited , global leader in allogeneic cellular medicines for inflammatory diseases, today provided a trading update, together with a comprehensive operational overview, as part of the Chief Executive's Annual General Meeting  address.For the quarter ending December 31, 2025, management expects gross revenue of more than US$30.0 million from sales of Ryoncil . This represents more than 37% increase on the US$21.9 million in gross revenue from Ryoncil in the prior quarter ended September 30, 2025.Mesoblast  is a world leader in developing allogeneic  cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company's proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.Mes","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","MESO"],"gpt_icon":0},{"id":"2585457162","title":"Mesoblast to Conduct Pivotal Ryoncil Trial in Adults With Severe Acute Graft Versus Host Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2585457162","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585457162?lang=en_us&edition=fundamental","pubTime":"2025-11-21 09:36","pubTimestamp":1763688983,"startTime":"0","endTime":"0","summary":"Mesoblast  will collaborate with the Blood and Marrow Transplant Clinical Trials Network on a pivotal trial of Ryoncil as part of a first-line regimen in adults with severe acute graft versus host disease refractory to corticosteroids, according to a Friday Australian bourse filing.The patients will be randomized in the trial as early as possible after corticosteroid refractoriness to receive ruxolitinib alone or combined with Ryoncil to give them the best chance of survival.The trial protocol will be provided to the US Food and Drug Administration to initiate enrollment in the first quarter of 2026. Mesoblast recently met with the US FDA to discuss the most appropriate patient population and timing of treatment in a pivotal trial of Ryoncil for adults with severe acute graft versus host disease.Ryoncil is already approved by the FDA in children and adolescents.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4218","HST","MSB.AU","BK7501","BK4588","BK4181","MESO","BK7508","BK4585","BK4139","BK7067"],"gpt_icon":0},{"id":"2585166564","title":"Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids","url":"https://stock-news.laohu8.com/highlight/detail?id=2585166564","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585166564?lang=en_us&edition=fundamental","pubTime":"2025-11-21 07:32","pubTimestamp":1763681520,"startTime":"0","endTime":"0","summary":"NEW YORK, Nov.  20, 2025  (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that given the high ra","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/20/3192470/0/en/Mesoblast-and-BMT-CTN-to-Initiate-Pivotal-Trial-of-Ryoncil-as-Part-of-First-Line-Regimen-in-Adults-with-Severe-Acute-GVHD-Refractory-to-Steroids.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","BK4150","MCW","BK4575","BK4535","MESO","BK4539","BK4192","BK4139","MSB","MSC"],"gpt_icon":0},{"id":"2584440766","title":"Mesoblast appoints James O’Brien as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2584440766","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584440766?lang=en_us&edition=fundamental","pubTime":"2025-11-17 18:45","pubTimestamp":1763376322,"startTime":"0","endTime":"0","summary":"Mesoblast (MESO) announced that in connection with the company’s transition to a fully integrated commercial organization it has appointed James O’...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mesoblast-appoints-james-obrien-as-cfo-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mesoblast-appoints-james-obrien-as-cfo-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MESO","BK4139"],"gpt_icon":0},{"id":"2584646044","title":"Mesoblast Appoints James O'Brien CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2584646044","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584646044?lang=en_us&edition=fundamental","pubTime":"2025-11-17 17:43","pubTimestamp":1763372632,"startTime":"0","endTime":"0","summary":"Mesoblast (MESO) said Monday it has appointed James O'Brien as its chief financial officer.O'Brien previously worked at different pharmaceutical companies, including Bristol-Myers Squibb (BMY) and Cognition Therapeutics (CGTX), the company said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0061475181.USD","LU1868837300.USD","LU1868836757.USD","BK4534","LU2125154935.USD","LU0321505439.SGD","LU1718418525.SGD","IE0002141913.USD","BK4559","LU0306806265.USD","LU0456855351.SGD","LU2125154778.USD","LU0868494617.USD","LU0882574055.USD","LU1291159041.SGD","LU1670710661.SGD","LU2360032135.SGD","LU2242646821.SGD","IE00BSNM7G36.USD","IE00BJJMRZ35.SGD","LU0237698245.USD","LU0321505868.SGD","BK4139","IE00BFTCPJ56.SGD","LU0306807586.USD","BK4532","LU1261432733.SGD","LU1670711123.USD","CGTX","IE00BJT1NW94.SGD","MESO","LU1093756325.SGD","LU1430594728.SGD","LU1093756168.USD","LU1585245621.USD","LU1074936037.SGD","BK4007","LU2133065610.SGD","BMY","IE00B2B36J28.USD","BK4585","LU0225771236.USD","LU1670711040.USD","LU1868837136.USD","LU0096364046.USD","LU0225284248.USD","LU1571399168.USD","LU1989771016.USD","LU2242652126.USD","IE00BFXG1179.USD"],"gpt_icon":0},{"id":"2584737614","title":"Press Release: James M. O'Brien Appointed Chief Financial Officer at Mesoblast","url":"https://stock-news.laohu8.com/highlight/detail?id=2584737614","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584737614?lang=en_us&edition=fundamental","pubTime":"2025-11-17 14:52","pubTimestamp":1763362320,"startTime":"0","endTime":"0","summary":"NEW YORK, Nov. 17, 2025  -- Mesoblast Limited , global leader in allogeneic cellular medicines for inflammatory diseases, today announced that in connection with the Company's transition to a fully integrated commercial organization it has appointed James M. O'Brien as its US-based Chief Financial Officer . Jim has extensive experience in all aspects of financial management and planning having spent the majority of his career with multi-national public and private companies in the life sciences, biotechnology, and pharmaceutical industries.Mesoblast  is a world leader in developing allogeneic  cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company's proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant red","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","MSC","BK4150","MSB","BK7067","BK7501","BK4575","BK4022","BK7508","BK4006","BMS","BK4139","R","CFO","MESO","MSB.AU"],"gpt_icon":0},{"id":"2584697095","title":"BRIEF-Mesoblast Appoints James M. O'brien As U.S.-Based CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2584697095","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584697095?lang=en_us&edition=fundamental","pubTime":"2025-11-17 09:47","pubTimestamp":1763344055,"startTime":"0","endTime":"0","summary":"BRIEF-Mesoblast Appoints James M. O'brien As U.S.-Based CFONov 17 (Reuters) - Mesoblast Ltd MSB.AX:APPOINTMENT OF CHIEF FINANCIAL OFFICERAPPOINTS JAMES M. O'BRIEN AS US-BASED CFOFurther company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nTUE2RGXVY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","MSB.AU","MESO","BK4139","BK7067","BK7508"],"gpt_icon":0},{"id":"2584697194","title":"Mesoblast Appoints New CFO Amidst Commercial Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2584697194","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584697194?lang=en_us&edition=fundamental","pubTime":"2025-11-17 09:38","pubTimestamp":1763343497,"startTime":"0","endTime":"0","summary":"Mesoblast Limited ( ($AU:MSB) ) has provided an update. Mesoblast Limited has appointed James M. O’Brien as its new Chief Financial Officer, a stra...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mesoblast-appoints-new-cfo-amidst-commercial-transition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mesoblast-appoints-new-cfo-amidst-commercial-transition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MESO"],"gpt_icon":0},{"id":"2584669489","title":"Mesoblast Appoints CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2584669489","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584669489?lang=en_us&edition=fundamental","pubTime":"2025-11-17 08:11","pubTimestamp":1763338304,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) appointed James M. O'Brien as chief financial officer, according to a Monday filing with the Australian bourse.The company's shares rose around 3% in recent Monday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7501","XAO.AU","BK7508","BK4139","XKO.AU","XJO.AU","MESO","MSB.AU"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mesoblast.com","stockEarnings":[{"period":"1week","weight":0.078},{"period":"1month","weight":0.3118},{"period":"3month","weight":0.1452},{"period":"6month","weight":0.8668},{"period":"1year","weight":0.1623},{"period":"ytd","weight":-0.0162}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.0096},{"month":2,"riseRate":0.5,"avgChangeRate":0.041084},{"month":3,"riseRate":0.5,"avgChangeRate":0.16594},{"month":4,"riseRate":0.4,"avgChangeRate":0.169294},{"month":5,"riseRate":0.5,"avgChangeRate":-0.027677},{"month":6,"riseRate":0.3,"avgChangeRate":-0.077641},{"month":7,"riseRate":0.6,"avgChangeRate":0.120859},{"month":8,"riseRate":0.2,"avgChangeRate":-0.055117},{"month":9,"riseRate":0.4,"avgChangeRate":0.04193},{"month":10,"riseRate":0.5,"avgChangeRate":-0.049086},{"month":11,"riseRate":0.8,"avgChangeRate":0.095285},{"month":12,"riseRate":0.545455,"avgChangeRate":0.012939}],"exchange":"NASDAQ","name":"Mesoblast","nameEN":"Mesoblast"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mesoblast(MESO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mesoblast(MESO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mesoblast,MESO,Mesoblast股票,Mesoblast股票老虎,Mesoblast股票老虎国际,Mesoblast行情,Mesoblast股票行情,Mesoblast股价,Mesoblast股市,Mesoblast股票价格,Mesoblast股票交易,Mesoblast股票购买,Mesoblast股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mesoblast(MESO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mesoblast(MESO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction